Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Viveka Björklund is active.

Publication


Featured researches published by Viveka Björklund.


The Journal of Pathology | 1999

Immunocytochemical detection and mapping of a cytokeratin 18 neo-epitope exposed during early apoptosis

Mathie P.G. Leers; Wendy Kölgen; Viveka Björklund; Tomas Bergman; Gordon Tribbick; Bengt Persson; Peter Björklund; Frans C. S. Ramaekers; Bertil Björklund; Marius Nap; Hans Jörnvall; Bert Schutte

A neo‐epitope in cytokeratin 18 (CK18) that becomes available at an early caspase cleavage event during apoptosis and is not detectable in vital epithelial cells is characterized. The monoclonal antibody M30, specific for this site, can be utilized specifically to recognize apoptotic cells, which show cytoplasmic cytokeratin filaments and aggregates after immunohistochemistry with M30, while viable and necrotic cells are negative. The number of cells recognized by the antibody increases after induction of apoptosis in exponentially growing epithelial cell lines and immunoreactivity is independent of the phosphorylation state of the cytokeratins. The generation of the M30 neo‐epitope occurs early in the apoptotic cascade, before annexin V reactivity or positive DNA nick end labelling. In a flow cytometric assay, the majority of the M30‐positive cells appear in the ‘apoptotic’ subG1 peak. Tests with synthetic peptides define positions 387–396 of CK18, with a liberated C‐terminus at the caspase cleavage site DALD‐S, as the ten‐residue epitope of M30. This epitope starts at the end of coil 2 of the predicted CK18 structure, at a probable hinge region, compatible with the sensitivity to proteolytic cleavage. The definition of a specific caspase cleavage site in CK18 as a neo‐epitope can be used for quantification of apoptotic epithelial cells with immunocytochemical techniques and is applicable to both fresh and formalin‐fixed material. Copyright


Experimental Biology and Medicine | 1961

The cytostat, an apparatus for automatically controlled continuous propagation of suspended cells.

Bertil Björklund; Viveka Björklund; Jan-Eric Paulsson

Summary The cytostat and its operation have been described. It would seem to be a useful aid to further in vitro studies of cell populations.


Photodiagnosis and Photodynamic Therapy | 2006

Early apoptotic responses in transgenic mouse mammary carcinoma for photodynamic therapy.

Heinrich Walt; Marius Nap; Ann M. Dorward; Mathie P.G. Leers; Barbara J. Tennent; Zsuzsanna Varga; Thomas Stallmach; Viveka Björklund; Wesley G. Beamer

BACKGROUND Male transgenic mice expressing the human RAS gene on an FVB strain background develop adenocarcinoma of the breast between 7 and 8 weeks of age. We have utilized this mammary tumour model to investigate apoptotic responses following photodynamic therapy (PDT) with a chlorin-based, water-soluble photosensitizer. METHODS Detection of apoptosis was accomplished by use of the antibody M30 against a neo-epitope of caspase-cleaved cytokeratin 18 that becomes available at an early stage of the apoptotic cascade. Mice bearing multiple tumours were injected with the photosensitizer intraperitoneally, and following a drug-light interval of 96h, 40J/cm(2) of 652nm laser light was applied to one tumour per animal, while the other tumours were protected from light to serve as host controls. The M30 antibody was used for standard immunohistochemistry of tumour sections and flow cytometric detection of epitope expression coupled to cell cycle analysis in tumour cell populations retrieved from paraffin blocks. RESULTS M30 staining was significantly increased within 2h following light treatment and persisted until 96h after treatment. Flow cytometric analysis for the S-phase fraction (SPF) of tumour cells post-PDT showed a substantial decrease in SPF at 2h post PDT, and recovery of SPF within 96h. CONCLUSIONS Cytokeratin 18 cleavage seems to be both an early and ongoing event during the cellular response to PDT. Calculating the M30/SPF ratio at both 2h and 96h suggested distinct cellular dynamics at early and late time points, and we propose the M30/SPF ratio as a tumour dynamic index (TDI) to monitor events post PDT.


International Archives of Allergy and Immunology | 1957

Antigenicity of Pooled Human Malignant and Normal Tissues by Cyto-Immunological Technique: Presence of an Insoluble, Heat-Labile Tumor Antigen

Bertil Björklund; Viveka Björklund


Experimental Cell Research | 2004

Keratin 8/18 breakdown and reorganization during apoptosis

Bert Schutte; Mieke Henfling; Wendy Kölgen; Maartje Bouman; Stephan Meex; Mathie P.G. Leers; Marius Nap; Viveka Björklund; Peter Björklund; Bertil Björklund; E. Birgitte Lane; M. Bishr Omary; Hans Jörnvall; Frans C. S. Ramaekers


Gynecologic Oncology | 2000

Apoptosis, bcl-2 Expression, and Proliferation in Benign and Malignant Endometrial Epithelium: An Approach Using Multiparameter Flow Cytometry

Hassan M. Morsi; Mathie P.G. Leers; Martin Radespiel-Tröger; Viveka Björklund; Hamdi El Kabarity; Marius Nap; Wolfram Jäger


International Archives of Allergy and Immunology | 1958

Antigenicity of Pooled Human Malignant and Normal Tissues by Cyto-Immunological Technique: II. Nature of Tumor Antigen

Bertil Björklund; Gunnar Lundblad; Viveka Björklund


Apmis | 2009

Immuno-histochemical localization of tissue polypeptide antigen (TPA) and carcino-embryonic antigen (CEA) in breast cancer. A comparative study.

Viveka Björklund; Bertil Björklund; Christian Wittekind; Sabine von Kleist


Archive | 1998

Apoptosis-related compounds and their use

Viveka Björklund; Bertil Björklund; Peter Björklund; Marius Nap; Frans C. S. Ramaekers; Bert Schutte


Journal of the National Cancer Institute | 1961

Antigenicity of Pooled Human Malignant and Normal Tissues by Cytoimmunological Technique. III. Distribution of Tumor Antigen

Bertil Björklund; Viveka Björklund; Ingegerd Hedlöf

Collaboration


Dive into the Viveka Björklund's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge